Tag Archive for: Destiny

Chief Business Officers: Shedding Light on Biotech’s Dealmakers 

Stephanie Bewick, Chief Business Officer at Destiny Pharma outlines her experiences of how a CBO maximises their company’s commercial appeal and lands deals in the biotech industry…

Destiny Pharma appoints Dr Yuri Martina as CMO

Destiny Pharma strengthens Executive Management Team with the appointment of Dr Yuri Martina as Chief Medical Officer Brighton, United Kingdom – 3rd May 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces the appointment of Dr. Yuri Martina as Chief Medical Officer (CMO). Read more

2021 and beyond with Destiny Pharma’s CEO, Neil Clark & CFO Shaun Claydon

Management of Destiny Pharma (DEST), the AIM listed infection prevention biotechnology company, offer an overview of the Company, their platform and their late stage clinical assets heading towards phase 3 trails. The team expand on the anti infective market, their COVID 19 program and the strength of their balance sheet. The Company finish with their […]

Destiny Pharma: Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus

Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus Strong support for potential of XF-73 nasal product as alternative to mupirocin Brighton, United Kingdom – 18 October 2021 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life […]